# Tibial Artery Hemodynamics Predict Foveal Avascular Zone Enlargement in Type 2 Diabetes

**Authors:** Lidia Ladea, Valentin Dinu, Ruxandra Coroleuca, Iulian Brezean, Eduard L. Catrina, Dana E. Nedelcu, Mihaela E. Vilcu, Cristian V. Toma, Adrian I. Georgevici, Christiana M. D. Dragosloveanu

PMC · DOI: 10.3390/diagnostics16040528 · Diagnostics · 2026-02-10

## TL;DR

This study finds that tibial artery blood flow measurements better predict retinal damage in type 2 diabetes compared to traditional pressure-based tests.

## Contribution

The study introduces a novel velocity-based tibial artery metric as a more sensitive indicator of retinal microvascular damage in diabetes.

## Key findings

- PT:AT ratio strongly correlates with foveal avascular zone enlargement (r = 0.471, p = 0.0086).
- ABI showed no significant association with retinal ischemia markers.
- Velocity-based metrics detect microvascular dysfunction better than pressure-based ABI.

## Abstract

(1) Background: Diabetic retinopathy and peripheral arterial disease co-occur through shared endothelial pathophysiology. Ankle-brachial index (ABI), the standard peripheral screening tool, demonstrates poor sensitivity (35%) in diabetic cohorts due to medial arterial calcification. We comparatively assessed the association of peak-systolic velocity of posterior/anterior tibial artery ratio (PT:AT) versus that of traditional pressure-based (ABI) with foveal avascular zone (FAZ), a marker of retinal ischemia, and thus hypothesized that PT:AT would demonstrate stronger association with FAZ compared to ABI in our cohort. (2) Methods: Cross-sectional pilot study of 30 type 2 diabetes mellitus patients. We aimed to enhance the robustness of our results using five convergent statistical methods. (3) Results: PT:AT showed strong association with FAZ (r = 0.471, p = 0.0086, 95% CI [0.13, 0.71]), with convergent evidence across all five analytical methods. ABI showed no effect (r = −0.024, p = 0.901, 95% CI [−0.38, 0.34]). We showed that velocity-based metrics identify microvascular dysfunction, whereas the pressure-based ABI does not. The mediation analysis showed that the relation of PT:AT to FAZ is not significantly mediated by the resistivity index of ophthalmic artery. (4) Conclusions: In this pilot study, velocity-based tibial hemodynamics showed a stronger cross-sectional relationship with retinal microvascular damage compared to pressure-based ABI. These preliminary findings suggest PT:AT assessment may complement ABI screening in diabetic foot clinics to identify patients requiring intensive retinal surveillance. Multicenter validation is required before clinical implementation.

## Linked entities

- **Diseases:** Type 2 Diabetes (MONDO:0005148), Diabetic retinopathy (MONDO:0005266), Peripheral arterial disease (MONDO:0005386)

## Full-text entities

- **Genes:** ELN (elastin) [NCBI Gene 2006] {aka ADCL1, SVAS, WBS, WS}, SLC2A1 (solute carrier family 2 member 1) [NCBI Gene 6513] {aka CSE, DYT17, DYT18, DYT9, EIG12, GLUT}, RENBP (renin binding protein) [NCBI Gene 5973] {aka RBP, RNBP}, AGER (advanced glycosylation end-product specific receptor) [NCBI Gene 177] {aka RAGE, SCARJ1, sRAGE}, SDC1 (syndecan 1) [NCBI Gene 6382] {aka CD138, SDC, SYND1, syndecan}
- **Diseases:** DR (MESH:D003930), retinal (MESH:D012173), diabetic neuropathy (MESH:D003929), diabetic microvascular damage (OMIM:603933), endothelial injury (MESH:D057772), Microvascular injury (MESH:D017566), PT (MESH:D006526), arterial calcification (MESH:D061205), amputation (MESH:C565682), diabetic foot (MESH:D017719), Atherosclerosis (MESH:D050197), diabetic damage (MESH:D058065), arterial stiffness (MESH:C566112), hypertension (MESH:D006973), diabetic kidney disease (MESH:D003928), MAC (MESH:D050380), nephropathy (MESH:D007674), Type 2 Diabetes (MESH:D003924), PAD (MESH:D058729), retinal damage (MESH:D012164), type 1 diabetes (MESH:D003922), peripheral disease (MESH:D010523), calcification (MESH:D002114), RI (MESH:D060467), Diabetes (MESH:D003920), critical limb ischemia (MESH:D000089802), hyperglycemia (MESH:D006943), arterial disease (MESH:D002539), peripheral vascular disease (MESH:D016491), inflammatory (MESH:D007249), injury to (MESH:D014947), coronary heart disease (MESH:D003327), visual acuity decline (MESH:D014786), OA (MESH:D010003), flow-limiting stenoses (MESH:D003251), FAZ (MESH:C537858), blindness (MESH:D001766), sclerosis (MESH:D012598), retinopathy (MESH:D058437), diabetic vasculopathy (MESH:D003925), metabolic toxicity (MESH:D065606)
- **Chemicals:** hydroxyapatite (MESH:D017886), FAZ (-), reactive oxygen species (MESH:D017382), hyaluronan (MESH:D006820), nitric oxide (MESH:D009569), AGEs (MESH:D017127)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12939209/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12939209/full.md

## References

38 references — full list in the complete paper: https://tomesphere.com/paper/PMC12939209/full.md

---
Source: https://tomesphere.com/paper/PMC12939209